Clinical Associate Professor, Pharmacotherapy
Department of Pharmacy Practice
College of Pharmacy
Oregon Health & Science University
3303 SW Bond Ave., CH12C
Portland, OR 97239
Phone: 503-494-0116
beardend@ohsu.edu
Infectious Diseases Fellowship, University of Illinois at Chicago, 2000
Pharmacy Practice Residency, University of Utah Hospitals and Clinics, 1998
Pharm.D., University of Illinois at Chicago, 1997
David Bearden practices in the area of adult infectious diseases. His research interests include the pharmacokinetics of antimicrobials in special populations, the approach to drug therapy in patients infected with resistant pathogens and pharmacist involvement in vaccine preventable diseases.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clinical Infectious Diseases. 2006;43:25-31.
Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis DP. Evaluation of antifungal usage in the surgical intensive care unit: A multi-institutional study. Mycoses. 2006;49:226-31.
Bearden DT, Holt T. State-wide impact of pharmacist-delivered adult influenza vaccinations. American Journal of Preventative Medicine. 2005;29:450-2.
Bearden DT. Macrolides. In: Fink MP, Abraham E, Kochanek PM, Vincent J, eds. Textbook of Critical Care. 5th ed, 2005. Philadelphia: Elsevier Science, Chapter 141.
Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. Clinical Pharmacokinetics. 2004;43:239-52.
Bearden DT, Allen GE. Impact of antimicrobial control programs on patient outcomes: Pharmacy perspective. Disease Management and Health Outcomes. 2003;11:723-36.
Bubalo JS, Blasdel CS, Bearden DT. Neutropenia after single-dose clindamycin for dental prophylaxis. Pharmacotherapy. 2003;23:101-3.
Bearden DT, Garvin CG. Recombinant human activated protein C for use in severe sepsis. Annals of Pharmacotherapy. 2002;36:1424-9.
Einhorn AE, Neuhauser MM, Bearden DT, et al. Extended-spectrum beta-lactamases (ESBLs): incidence, risk factors, and outcomes. Pharmacotherapy. 2002;22:14-20.
Bearden DT, Neuhauser MM, Garey KW. Telithromycin: a review of the first ketolide. Pharmacotherapy. 2001;21:1204-1222.
Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy. 2001;21:224-232S.
Bearden DT, Muncey LA. The effect of amiloride on amphotericin B-induced hypokalaemia. Journal of Antimicrobial Chemotherapy. 2001;48:109-11.
Danziger LH, Itokazu G, Bearden DT. Infectious diarrhea. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed, 2001. Baltimore: Lippincott, Williams & Wilkins, Chapter 60.
Delgado G, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin/dalfopristin: an overview. Pharmacotherapy. 2000;20:1469-85.
Bearden DT, Rodvold KA. Dosage adjustments for antibiotics in obese patients: Applying clinical pharmacokinetics. Clinical Pharmacokinetics. 2000;38:415-26.
